Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

In older/unfit newly diagnosed patients with FLT3 mutated acute myeloid leukemia (AML), lower intensity chemotherapy (LIC) in combination with either a FLT3 inhibitor or with venetoclax results in poor overall survival (median 8 to 12.5 months). We performed a retrospective analysis of 87 newly diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Yilmaz, Musa, Kantarjian, Hagop, Short, Nicholas J., Reville, Patrick, Konopleva, Marina, Kadia, Tapan, DiNardo, Courtney, Borthakur, Gautam, Pemmaraju, Naveen, Maiti, Abhishek, Jabbour, Elias, Jain, Nitin, Issa, Ghayas, Takahashi, Koichi, Sasaki, Koji, Ohanian, Maro, Pierce, Sherry, Tang, Guillin, Loghavi, Sanam, Patel, Keyur, Wang, Sa A., Garcia-Manero, Guillermo, Andreeff, Michael, Ravandi, Farhad, Daver, Naval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061716/
https://www.ncbi.nlm.nih.gov/pubmed/35501304
http://dx.doi.org/10.1038/s41408-022-00670-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061716/
https://www.ncbi.nlm.nih.gov/pubmed/35501304
http://dx.doi.org/10.1038/s41408-022-00670-0

Ejemplares similares